Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence

G Haidar, M Boeckh, N Singh - The Journal of infectious …, 2020 - academic.oup.com
This review focuses on recent advances in the field of cytomegalovirus (CMV). The 2 main
strategies for CMV prevention are prophylaxis and preemptive therapy. Prophylaxis …

Biliary complications after liver transplantation

B Nemes, G Gámán, A Doros - Expert review of gastroenterology & …, 2015 - Taylor & Francis
Biliary complications (BCs) remain one of the most outstanding factors influencing long-term
results after orthotopic liver transplantation. The authors carried out a systematic overview of …

Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the …

JM Neuberger, WO Bechstein, DRJ Kuypers… - …, 2017 - journals.lww.com
Short-term patient and graft outcomes continue to improve after kidney and liver
transplantation, with 1-year survival rates over 80%; however, improving longer-term …

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

PD Griffiths, A Stanton, E McCarrell, C Smith, M Osman… - The Lancet, 2011 - thelancet.com
Background Cytomegalovirus end-organ disease can be prevented by giving ganciclovir
when viraemia is detected in allograft recipients. Values of viral load correlate with …

Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial

O Witzke, IA Hauser, M Bartels, G Wolf, H Wolters… - …, 2012 - journals.lww.com
Background. Cytomegalovirus (CMV) prevention can be achieved by prophylaxis or
preemptive therapy. We performed a prospective randomized trial to determine whether …

[HTML][HTML] Infections in liver transplant recipients

FA Romero, RR Razonable - World journal of hepatology, 2011 - ncbi.nlm.nih.gov
Liver transplantation is a standard life-saving procedure for the treatment of many end-stage
liver diseases. The success of this procedure may be limited by infectious complications. In …

Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor–based immunosuppression? A systematic review and meta-analysis

J Andrassy, VS Hoffmann, M Rentsch, M Stangl… - …, 2012 - journals.lww.com
Background Cytomegalovirus (CMV) is a common opportunistic infection after solid organ
transplantation. Cytomegalovirus causes increased morbidity, mortality, and reduced …

Viral infections in solid organ transplant recipients: novel updates and a review of the classics

G Haidar, N Singh - Current opinion in infectious diseases, 2017 - journals.lww.com
Ongoing trials to optimize CMV prophylaxis and treatment, and outcomes of HIV-to-HIV
organ transplantation in the United States, have significant implications to optimize …

Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not …

D Abate, A Saldan, M Fiscon, S Cofano… - The Journal of …, 2010 - academic.oup.com
Background. The ultimate goal of organ transplantation is the reestablishment of organ
function and the restoration of a solid immunity to prevent the assault of potentially deadly …

GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients

J Torre-Cisneros, MC Fariñas, JJ Castón… - … y microbiologia clinica, 2011 - Elsevier
Cytomegalovirus infection remains a major complication of solid organ transplantation. In
2005 the Spanish Transplantation Infection Study Group (GESITRA) of the Spanish Society …